Chronic selective hypertriglyceridemia impairs endothelium-dependent vasodilatation in rats

Cardiovascular Research

Volumn 42, Issue 3, 1999, Pages 783-793

  Kusterer, Klaus ^a   Pohl, Tilla ^a   Fortmeyer, Hans Peter ^a   März, Winfried ^b   Scharnagl, Hubert ^b   Oldenburg, Anke ^a   Angermüller, Sabine ^c   Fleming, Ingrid ^a   Usadel, Klaus H ^a   Busse, Rudi ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Endothelium; Nitric oxide; Rat; Superoxide anion

Indexed keywords

NITRIC OXIDE; SUPEROXIDE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; HISTOPATHOLOGY; HYPERTRIGLYCERIDEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RISK FACTOR; VASCULAR ENDOTHELIUM; VASODILATATION;

ACETYLCHOLINE; ANIMALS; AORTA; ARGININE; BLOTTING, WESTERN; CAROTID ARTERIES; CHRONIC DISEASE; ENDOTHELIUM, VASCULAR; HINDLIMB; HYPERTRIGLYCERIDEMIA; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROARGININE; NITROPRUSSIDE; RATS; RATS, SPRAGUE-DAWLEY; REGIONAL BLOOD FLOW; SUPEROXIDES; VASODILATION;

EID: 0033066016     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00331-9     Document Type: Article

References (46)

1. Dorr A.E., Gundersen K., Schneider J.C. Jr., Spencer T.W., Martin W.B. Colestipol hydrochloride in hypercholesterolemic patients - effect on serum cholesterol and mortality. J. Chron. Dis. 31:1978;5-14.
2. Scandanavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the scandanavian simvastatin survival study (4S). Lancet 1994;344:1383-1389.
3. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. J Am Med Assoc 1984;251:365-374.
4. Yu S.-M., Huang Z.-S., Wang C.-Y., Teng C.-M. Effects of hyperlipidemia on the vascular reactivity in the Wistar-Kyoto and spontaneously hypertensive rats. Eur. J. Pharmacol. 248:1993;289-295.
5. Verbeuren T.J., Jordaens F.H., Zonnekeyn L.L.et al. Effect of hypercholesterolemia on vascular reactivity in the rabbit. Circ. Res. 53:1983;63.
6. Hodis H.N., Mack W.N. Triglyceride-rich lipoproteins and the progression of coronary artery disease. Curr. Opin. Lipidol. 6:1995;209-214.
7. Austin M.A. Plasma triglyceride and coronary heart disease. Arterioscler. Thromb. 11:1991;2-14.
8. Blankenhorn DH, Azen SP, Kramsch DM, et al., the MARS Research Group. Coronary angiographic changes with lovastatin therapy. The monitored Atherosclerosis Regression Study (MARS). Ann. Intern. Med. 1994;119:969-976.
9. Hodis H.N., Mack W.J., Azen S.P.et al. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantative coronary angiography in a controlled trial of lovastatin. Circulation. 90:1994;42-49.
10. Assmann G., Schulte H., von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle aged men. Am. J. Cardiol. 77:1996;1179-1184.
11. Shepherd J., Cobbe S.M., Ford I.et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. New Engl. J. Med. 333:1995;1301-1307.
12. Sacks F.M., Pfeffer M.A., Moye L.A.et al. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. New Engl. J. Med. 335:1996;1001-1009.
13. Busse R., Fleming I. Endothelial dysfunction in atherosclerosis. J Vasc Res. 33:1996;181-194.
14. Busse R., Fleming I. Regulation and functional consequences of endothelial nitric oxide formation. Ann. Med. 27:1995;331-340.
15. Egashira K., Inou T., Hirooka Y.et al. Evidence of impaired endothelium-dependent coronary vasodilation in patients with angina pectoris and normal angiograms. New Engl. J. Med. 328:1993;1659-1664.
16. Zeiher A.M., Drexler H., Wollschläger H., Just H. Endothelial dysfunction of the coronary microvasculature is associated with impaired coronary blood flow regulation in patients with early atherosclerosis. Circulation. 84:1991;1984-1992.
17. Drexler H., Zeiher A.M., Meinzer K., Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet. 338:1991;1546-1550.
18. Girerd X.L., Hirsch A.T., Cooke J.P., Dzau V.J., Creager M.A. L-Arginine augments endothelium-dependent vasodilation in cholesterol-fed rabbits. Circ. Res. 315:1990;1046-1051.
19. Cooke J.P., Singer A.H., Tsao P.et al. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J. Clin. Invest. 90:1992;1168-1172.
20. Fleming I., Fisslthaler B., Busse R. Calcium signaling in endothelial cells involves activation of tyrosine kinases and leads to activation of MAP kinase. Circ. Res. 76:1995;522-529.
21. Stolba P., Opltova H., Husek P.et al. Adrenergic overactivity and insulin resistance in nonobese hereditary hypertriglyceridemic rats. Ann. New York Acad. Sci. 683:1993;281-288.
22. Klimes I., Vrána A., Kunes J.et al. Hereditary hypertriglyceridemic rat: a new animal model of metabolic alterations in hypertension. Blood Press. 4:1995;137-142.
23. Wilson P.W., Abbott R.D., Castelli W.P. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis. 8:1988;737-741.
24. Abbott R.D., Wilson P.W., Kannel W.B., Castelli W.P. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study. Arteriosclerosis. 8:1988;207-211.
25. Gordon D.J., Probstfield J.L., Garrison R.J.et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 79:1989;8-15.
26. Stary H.C., Chandler A.B., Glagov S.et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. Circulation. 89:1994;2462-2478.
27. Freiman P.C., Mitchell G.G., Heistad D.D., Armstrong M.L., Harrison D.G. Atherosclerosis impairs endothelium-dependent vascular relaxation to acetylcholine and thrombin in primates. Circ. Res. 58:1986;783-789.
28. Bosaller C., Habib G.B., Yamamoto H.et al. Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine-5′-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta. J. Clin. Invest. 79:1987;170-182.
29. Bauersachs J., Popp R., Hecker M.et al. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation. 94:1996;3341-3347.
30. Dubios-Randé J-.L., Zelinsky R., Roudot F.et al. Effects of infusion of L-arginine into the left anterior descending coronary artery on acetylcholine-induced vasoconstriction of human atheromatous coronary arteries. Am. J. Cardiol. 70:1992;1269-1275.
31. Imaizumi T., Hirooka Y., Masaki H. Effects of L-arginine on forearm vessels and responses to acetylcholine. Hypertension. 20:1992;511-517.
32. Panza J.A., Casino P.R., Badar D.M., Quyyumi A.A. Effect of increased avaliability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Circulation. 87:1993;1475-1481.
33. Casino P.R., Kilcoyne C.M., Quyyumi A.A., Hoeg J.M., Panza J.A. Investigation of decreased availability of nitric oxide precursor as the mechanism responsible for impaired endothelium-dependent vasodilation in hypercholesterolemic patients. J. Am. Coll. Cardiol. 23:1994;844-850.
34. Calver A., Collier J., Vallance P. Dilator actions of arginine in human peripheral vasculature. Clin. Sci. 81:1991;695-700.
35. Hutcheson I.R., Smith J.A., Griffith T.M. Abolition of flow-dependent EDRF release before that evoked by agonists in hypercholesterolaemic rabbits. Br. J. Pharmacol. 113:1994;190-194.
36. Pritchard K.A. Jr., Groszek L., Smalley D.M.et al. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ. Res. 77:1995;510-518.
37. Kurose I., Wolf R., Grisham M.B., Granger D.N. Effects of an endogenous inhibitor of nitric oxide synthesis on postcapillary venules. Am. J. Physiol. 268:1995;H2224-H2231.
38. Clancy R.M., Leszczynska-Piziak J., Abramson S.B. Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase. J. Clin. Invest. 90:1992;1116-1121.
39. Wiedermann C.J., Sitte B., Zilian U.et al. Inhibition of superoxide anion release from circulating neutrophils by L-arginine in man. Clin. Invest. 71:1993;985-989.
40. Bauersachs J., Bouloumié A., Mülsch A.et al. Vasodilator dysfunction in aged spontaneously hypertensive rats: changes in NO synthase III and soluble guanylyl expression and in superoxide anion production. Cardiovasc. Res. 37:1998;772-779.
41. Ohara Y., Peterson T.E., Harrison D.G. Hypercholesterolemia increases endothelial superoxide anion production. J. Clin. Invest. 91:1993;2546-2551.
42. Grunfeld S., Hamilton C.A., Mesaros S.et al. Role of superoxide in the depressed nitric oxide production by the endothelium of genetically hypertensive rats. Hypertension. 26:1995;854-857.
43. Rajagopalan S., Kurz S., Münzel T.et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. J. Clin. Invest. 97:1996;1916-1923.
44. Bouloumié A., Bauersachs J., Linz W.et al. Endothelial dysfunction coincides with an enhanced NO synthase expression and superoxide anion production. Hypertension. 30:1997;934-941.
45. Ross R., Glomset J., Harker L. Response to injury and atherogenesis. Am. J. Pathol. 86:1977;675-684.
46. Zeiher A.H., Drexler H., Wollschläger H., Just H. Modulation of coronary vasomotor tone in humans: progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation. 83:1991;391-401.